Skip to content

Assessment of Vitamin B12 Bioavailability From Egg

Assessment of Vitamin B12 Bioavailability From Egg

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01366937
Enrollment
10
Registered
2011-06-06
Start date
2007-08-31
Completion date
2009-09-30
Last updated
2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability of Vitamin B12 From Chicken Eggs

Keywords

vitamin B12, egg, 14C, fecal excretion

Brief summary

The hypothesis of this study is that chicken eggs can be enriched in vivo with 14C-B12 and fed to healthy human subjects to determine B12 bioavailability from eggs. The goal of this research is to enrich eggs in vivo with radioactively labeled vitamin B12 to a level that allows us to feed the enriched eggs to humans and determine how much of the vitamin B12 is digested and absorbed into the body. This will tell us if eggs are a good dietary source of vitamin B12. Importantly, sensitive technology available at the Lawrence Livermore National Laboratories allows us to measure very low amounts of radioactive vitamin B12. This allows us to do this experiment with a level of radioactive B12 that is not harmful to animals or humans. The results of the investigators first experiment indicate that the investigators can inject radioactively labeled vitamin B12 into a laying hen and detect the radioactive vitamin B12 in the eggs at a level sufficient for feeding to humans in a bioavailability study.

Interventions

None listed

Sponsors

USDA, Western Human Nutrition Research Center
Lead SponsorFED

Study design

Observational model
CASE_ONLY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* normal healthy subjects, adequate B12 status and absorptive capacity and the availability to complete the protocol.

Exclusion criteria

* any chronic health disorder, anemia of any kind, renal insufficiency, and pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Fecal enrichment of 14COver the course of 8 days after dosing with 14C labeled egg

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026